Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Influenza Vaccination Among Individuals With Type 1 Diabetes in Denmark: Coverage, Persistence, and Determinants, 2015-2022.

Diabetes, obesity & metabolism·2026
Same author

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.

European heart journal·2026
Same author

Extending inferences from a randomized trial to trial-eligible and treatment-candidate target populations: examples of generalizability and transportability.

Epidemiology (Cambridge, Mass.)·2026
Same author

Authors' reply: Poor long-term cardiovascular risk factor management after acute coronary syndrome: An observational cohort study.

Journal of internal medicine·2026

相关实验视频

Updated: Sep 9, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K

在心肌梗塞中ACE抑制剂或血管素受体阻断剂的长期有效性

Anna B C Humphreys1, Bertil Lindahl2, Anita Berglund1

  • 1Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden.

European heart journal. Cardiovascular pharmacotherapy
|August 31, 2025
PubMed
概括
此摘要是机器生成的。

血管激素转化酶抑制剂 (ACEi) 和血管激素受体阻断剂 (ARB) 似乎对心肌梗塞和保留射出小部分的患者没有益处. 在接受或不接受这些常见心脏药物的患者中,该研究发现了类似的综合结果.

关键词:
血管素受体阻断剂氨酸转化酶抑制剂心肌梗塞观察性研究保存的左心室喷射分数目标试验模拟

更多相关视频

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

28.1K

相关实验视频

Last Updated: Sep 9, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

28.1K

科学领域:

  • 心脏病学
  • 药理学
  • 临床研究

背景情况:

  • 血管激素转化酶抑制剂 (ACEi) 和血管激素受体阻断剂 (ARB) 是已知的心肌梗塞 (MI) 治疗方法,其左心室喷射分数 (LVEF) 减少.
  • 在心脏病发作和保存LVEF (≥50%) 的患者中,ACEi/ ARB的疗效仍然不确定.

研究的目的:

  • 研究ACEi/ ARBs在预防心脏病发作和维护LVEF患者的不良结果方面的有效性.
  • 为了确定ACEi/ARB在这个特定的患者群体中是否具有显著的益处.

主要方法:

  • 采用瑞典医疗登记的目标试验模拟 (2010年9月 - 2021年6月).
  • 包括75岁以下心脏病发作和LVEF≥50%的患者.
  • 用于混调整估计治疗意图和每条协议效应的反向概率加权.

主要成果:

  • 共有10,697名患者接受了ACEi/ ARB,而4,730人没有.
  • 综合结局 (死亡,心脏病发作或心力衰竭) 的估计5年风险在各组之间相似 (7. 8% vs 8. 1%).
  • 调整后的分析也显示了类似的风险 (-0.2%的风险差异).

结论:

  • 在心脏病发作和保存LVEF的患者中,ACEi/ ARB治疗没有显著的益处.
  • 在治疗和非治疗组中,死亡,心脏病发作或心力衰竭的综合风险相似.